Researchers at the Washington School of Medicine have developed a new test to help them understand why the toxin, Amyloid Beta Protein, builds up in the brain of Alzheimer's patients. This, in turn, could help them determine which drugs to put forward for clinical trials and at what doses. Read the full story here: http://news.bbc.co.uk/1/hi/health/5109510.stm.
April 2006 May 2006 June 2006 July 2006 August 2006 September 2006 October 2006 November 2006 December 2006